Brokerages predict that Veru Inc (NASDAQ:VERU) will post sales of $6.33 million for the current quarter, Zacks reports. Three analysts have provided estimates for Veru’s earnings, with the highest sales estimate coming in at $8.80 million and the lowest estimate coming in at $4.50 million. Veru posted sales of $3.69 million during the same quarter last year, which suggests a positive year over year growth rate of 71.5%. The business is scheduled to issue its next quarterly earnings results on Tuesday, January 1st.

According to Zacks, analysts expect that Veru will report full-year sales of $16.31 million for the current year, with estimates ranging from $13.16 million to $19.46 million. For the next year, analysts forecast that the firm will post sales of $31.09 million per share, with estimates ranging from $22.00 million to $36.97 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Veru.

Veru (NASDAQ:VERU) last issued its earnings results on Tuesday, August 14th. The company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.07). Veru had a negative net margin of 130.26% and a negative return on equity of 38.09%. The firm had revenue of $5.50 million during the quarter, compared to analyst estimates of $5.20 million.

VERU has been the topic of a number of research analyst reports. Maxim Group started coverage on Veru in a report on Tuesday, July 3rd. They issued a “buy” rating on the stock. Zacks Investment Research lowered Veru from a “hold” rating to a “sell” rating in a research report on Tuesday, August 21st. HC Wainwright set a $5.00 price objective on Veru and gave the company a “buy” rating in a research report on Tuesday, August 28th. Dawson James reissued a “buy” rating on shares of Veru in a research report on Monday, June 25th. Finally, ValuEngine raised Veru from a “hold” rating to a “buy” rating in a research report on Wednesday, August 15th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $5.83.

A hedge fund recently bought a new stake in Veru stock. ACG Wealth acquired a new stake in Veru Inc (NASDAQ:VERU) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 77,000 shares of the company’s stock, valued at approximately $156,000. ACG Wealth owned 0.14% of Veru at the end of the most recent reporting period. 5.20% of the stock is owned by institutional investors and hedge funds.

Veru stock traded up $0.03 during midday trading on Friday, reaching $1.97. The stock had a trading volume of 976 shares, compared to its average volume of 113,324. Veru has a twelve month low of $0.90 and a twelve month high of $3.00. The stock has a market capitalization of $107.25 million, a P/E ratio of -8.16 and a beta of 0.69. The company has a current ratio of 1.01, a quick ratio of 0.80 and a debt-to-equity ratio of 0.12.

About Veru

Veru Inc operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

See Also: How Do Tariffs Affect Trade Balances?

Get a free copy of the Zacks research report on Veru (VERU)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with's FREE daily email newsletter.